These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Quantifying gene expression in prostate carcinoma. Which endogenous reference genes are suitable?]. Jung M; Ohl F; Stephan C; Rabien A; Kristiansen G; Radonić A; Loening SA; Jung K Urologe A; 2007 Sep; 46(9):1083-4. PubMed ID: 17628775 [No Abstract] [Full Text] [Related]
7. The natural history of prostatic carcinoma. Busch C Scand J Urol Nephrol Suppl; 1988; 110():23-9. PubMed ID: 3187413 [No Abstract] [Full Text] [Related]
8. Prostate cancer. Nelson WG; De Marzo AM; Isaacs WB N Engl J Med; 2003 Jul; 349(4):366-81. PubMed ID: 12878745 [No Abstract] [Full Text] [Related]
9. [Morphometric diagnostics of the prostate precancer and cancer by examination of ploidy]. Gundorova LV; Avtandilov GG; Saniev KB; Zaĭrat'iants OV Arkh Patol; 2003; 65(4):46-50. PubMed ID: 14518195 [TBL] [Abstract][Full Text] [Related]
10. Editorial comment from Dr Simmons to prostate HistoScanning: a screening tool for prostate cancer? Simmons LA Int J Urol; 2013 Dec; 20(12):1192. PubMed ID: 23594191 [No Abstract] [Full Text] [Related]
11. Editorial comment from Dr Salomon to prostate HistoScanning: a screening tool for prostate cancer? Salomon G Int J Urol; 2013 Dec; 20(12):1191. PubMed ID: 23594168 [No Abstract] [Full Text] [Related]
12. Improving Prostate Cancer Screening and Diagnosis: Health Policy and Biomarkers Beyond PSA. Patel HD; Chalfin HJ; Carter HB JAMA Oncol; 2016 Jul; 2(7):867-8. PubMed ID: 27031887 [No Abstract] [Full Text] [Related]
13. Prostate cancer: towards the standardization and synthesis of morphology, genetics, and prognosis. Berney D; Cheng L Histopathology; 2012 Jan; 60(1):1-3. PubMed ID: 22212074 [TBL] [Abstract][Full Text] [Related]
14. [Comparative evaluation of expression patterns of established and new prostate carcinoma associated genes with reference to suitability for molecular biologic diagnostic and prognostic factors]. Füssel S; Unversucht S; Meye A; Kunze D; Baretton G; Toma M; Haase M; Grimm MO; Seifert J; Höfling C; Koch R; Wirth MP Urologe A; 2007 Sep; 46(9):1088-9. PubMed ID: 17624512 [No Abstract] [Full Text] [Related]
15. [New urinary markers in patients with prostatic cancer: analysis of the screening problem]. Jiménez-Pacheco A; Peinado-Herreros JM; López-Luque A; Iríbar Ibabe MC Rev Med Chil; 2012 May; 140(5):686-7. PubMed ID: 23096680 [No Abstract] [Full Text] [Related]
16. Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme. Goldstraw MA BJU Int; 2013 Apr; 111(4):E140-1. PubMed ID: 23551450 [No Abstract] [Full Text] [Related]
17. [Molecular high throughput research in prostate carcinoma]. Schlomm T; Sültmann H; Poustka A; Sauter G; Hellwinkel OJ; Huland H Urologe A; 2007 Sep; 46(9):1097-100. PubMed ID: 17628772 [No Abstract] [Full Text] [Related]
18. Editorial comment: Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme. Albertsen PC BJU Int; 2012 Dec; 110(11):1653. PubMed ID: 22984891 [No Abstract] [Full Text] [Related]
19. Androgen action during prostate carcinogenesis. Wang D; Tindall DJ Methods Mol Biol; 2011; 776():25-44. PubMed ID: 21796518 [TBL] [Abstract][Full Text] [Related]
20. [Organization of data and tissue banks for new prognostic factors in adenocarcinoma of the prostate. An interdisciplinary uropathologic approach]. Burger M; Hartmann A; Stoehr R; Hofstaedter F; Kneitz B; Riedmiller H; Wieland WF; Denzinger S Urologe A; 2007 Sep; 46(9):1094. PubMed ID: 17628773 [No Abstract] [Full Text] [Related] [Next] [New Search]